drugset / Trial / NCT02199223

Regorafenib + Panitumumab for Colorectal Cancers

NCT02199223

Phase 1 Terminated 2 enrolled University of Utah
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety of regorafenib and panitumumab

Timeline

Start
2014-06
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Panitumumab Monoclonal antibody
Subject Regorafenib Small molecule

Indications